Cover Image

Letter: Fecal VOCs in Lynch Syndrome: Sample Stability, Specificity and Statistical Validation

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xidi Yang, Yue Wang, Fa Tian
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome—A Prospective Longitudinal Multicentre Study
by: Elsa L. S. A. van Liere, et al.
Published: (2024)

Stability of Classification Systems for Irritable Bowel Syndrome
by: Mais Khasawneh, et al.
Published: (2025)

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
by: Kim W. E. Sweerts, et al.
Published: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
by: Qiong Yi, et al.
Published: (2024)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
by: Ahmed Helmy
Published: (2025)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
by: Gamal Shiha, et al.
Published: (2025)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
by: Vivek C. Goodoory, et al.
Published: (2024)

Letter: From Descriptive Epidemiology to Clinical Imperative—Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease
by: DuJiang Yang, et al.
Published: (2025)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
by: Xueneng Yang, et al.
Published: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
by: David Tornai, et al.
Published: (2026)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
by: Sifu Yang
Published: (2025)

Letter: Methodological Flaws and Clinical Gaps—A Critique of TAF / TDF 5‐Year Data in East Asian CHB
by: Zhiyao Shi, et al.
Published: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
by: Leyu Zhou, et al.
Published: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
by: Jiamei Wang, et al.
Published: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
by: Yaomin Wang, et al.
Published: (2024)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease
by: Jiahao Liu, et al.
Published: (2026)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
by: Xiaoqing Yang, et al.
Published: (2026)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
by: Qiang Hu, et al.
Published: (2024)

Letter: Is Routine ECG Monitoring Redundant During Terlipressin Therapy in HRS ‐ AKI ?
by: Xing Wang
Published: (2025)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
by: Liang Jiao, et al.
Published: (2026)

Letter: Intestinal Ultrasound‐Prioritising Progress
by: Kacie H. Denton, et al.
Published: (2026)

Letter: Irritable bowel syndrome and antibiotics
by: George F. Longstreth
Published: (2024)

Letter: Shifting focus—From ChatGPT to specialised medical LLMs
by: Shuo Wang, et al.
Published: (2024)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
by: Hong‐Li Liu, et al.
Published: (2026)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
by: Zhen Deng, et al.
Published: (2025)

Letter: Reflections on the role of over‐the‐scope clips in high‐risk upper gastrointestinal bleeding
by: Yajie Wang, et al.
Published: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
by: Fang Yan, et al.
Published: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
by: Juntao Lu, et al.
Published: (2026)

Letter: Resmetirom for treatment of MASH with children and adolescents
by: Yong‐Hai Zhou, et al.
Published: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
by: Xinli Chen, et al.
Published: (2024)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
by: Jiwon Yang, et al.
Published: (2025)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
by: Jian Wang, et al.
Published: (2024)

Letter: Post‐HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations—A Critical Research Need
by: Zihe Guan, et al.
Published: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
by: Hong‐Li Liu, et al.
Published: (2026)

Letter: Reinterpreting the Role of Microbiota‐Driven Nitric Oxide in Cirrhotic Portal Hypertension—A Maladaptive Compensatory Response?
by: Meiyu Yang, et al.
Published: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
by: Christophe Corpechot
Published: (2026)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
by: Richard Pollok
Published: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
by: Fernanda Cristofori, et al.
Published: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
by: Kyle Staller, et al.
Published: (2024)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
by: Mathieu Uzzan, et al.
Published: (2025)